Management of oral antiplatelet agents and anticoagulation therapy before bronchoscopy

• Published in: Journal of thoracic disease Vol. 9; no. Suppl 10; pp. S1022 - S1033
• Main Authors: Youness, Houssein A, Keddissi, Jean, Berim, Ilya, Awab, Ahmed
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 01.09.2017
• Subjects: Review; Anticoagulation; antiplatelet therapy; newer oral anticoagulation agents (NOAC); bronchoscopy
• ISSN: 2072-1439; 2077-6624
• DOI: 10.21037/jtd.2017.05.45

Although, bronchoscopy is a relatively safe procedure, small amount of bleeding in the airway can have serious consequences. Careful consideration of the risks of diagnostic and therapeutic bronchoscopic intervention can help minimize potential complications. With increasing number of patients using antiplatelet and anticoagulation therapies, strategies for minimizing thromboembolic and operative bleeding events need to be included in the risk and benefit analyses. Growing evidence suggests that aspirin is safe and does not increase bleeding during bronchoscopy. In addition, despite small studies reporting that it may be safe to perform bronchoscopic procedures that have low risk for bleeding such as endobronchial ultrasound with transbronchial needle aspiration on clopidogrel, it is still recommended to hold it for 7 days prior to performing elective bronchoscopy. It is recommended to hold vitamin K antagonist, as well as new oral anticoagulation agents prior to bronchoscopy. The timing for pre-procedural discontinuation of anticoagulation therapy and the decision to bridge depend on the agent used, the renal function and the thromboembolic risk. In this review article, we will discuss available data regarding management of anticoagulation and antiplatelet therapy as it applies to bronchoscopic procedures.